44.36
1.32%
0.58
Overview
News
Price History
Option Chain
Financials
Why CVS Down?
Discussions
Forecast
Stock Split
Dividend History
Cvs Health Corp stock is traded at $44.36, with a volume of 19.00M.
It is up +1.32% in the last 24 hours and down -21.94% over the past month.
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the us. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 26 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all its existing business lines.
See More
Previous Close:
$43.78
Open:
$43.72
24h Volume:
19.00M
Relative Volume:
1.53
Market Cap:
$55.82B
Revenue:
$368.91B
Net Income/Loss:
$5.02B
P/E Ratio:
6.6908
EPS:
6.63
Net Cash Flow:
$1.69B
1W Performance:
-10.15%
1M Performance:
-21.94%
6M Performance:
-27.28%
1Y Performance:
-42.57%
Cvs Health Corp Stock (CVS) Company Profile
Name
Cvs Health Corp
Sector
Industry
Phone
(401) 765-1500
Address
ONE CVS DR., WOONSOCKET
Compare CVS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
CVS
Cvs Health Corp
|
44.36 | 55.82B | 368.91B | 5.02B | 1.69B | 3.94 |
UNH
Unitedhealth Group Inc
|
500.13 | 460.26B | 389.07B | 14.32B | 13.10B | 15.35 |
ELV
Elevance Health Inc
|
365.96 | 84.87B | 174.02B | 6.42B | 871.00M | 27.43 |
CI
Cigna Group
|
276.92 | 77.03B | 229.75B | 3.04B | 5.18B | 10.60 |
CNC
Centene Corp
|
59.58 | 30.08B | 161.73B | 3.07B | 245.00M | 5.76 |
Cvs Health Corp Stock (CVS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-03-24 | Upgrade | Deutsche Bank | Hold → Buy |
Nov-18-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
Oct-10-24 | Upgrade | Barclays | Equal Weight → Overweight |
Oct-04-24 | Upgrade | TD Cowen | Hold → Buy |
May-30-24 | Initiated | Robert W. Baird | Neutral |
May-07-24 | Downgrade | TD Cowen | Buy → Hold |
May-02-24 | Downgrade | UBS | Buy → Neutral |
May-01-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
May-01-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
Mar-06-24 | Initiated | Barclays | Equal Weight |
Feb-26-24 | Initiated | Leerink Partners | Outperform |
Dec-22-23 | Initiated | HSBC Securities | Buy |
Sep-19-23 | Upgrade | Evercore ISI | In-line → Outperform |
Sep-12-23 | Upgrade | Wolfe Research | Peer Perform → Outperform |
Aug-18-23 | Downgrade | Edward Jones | Buy → Hold |
May-26-23 | Initiated | Piper Sandler | Overweight |
Apr-21-23 | Initiated | Cantor Fitzgerald | Overweight |
Jan-03-23 | Downgrade | Evercore ISI | Outperform → In-line |
Nov-23-22 | Resumed | Morgan Stanley | Overweight |
Jun-17-22 | Initiated | Loop Capital | Buy |
May-27-22 | Downgrade | Bernstein | Outperform → Mkt Perform |
Mar-29-22 | Downgrade | Deutsche Bank | Buy → Hold |
Feb-11-22 | Downgrade | Raymond James | Strong Buy → Outperform |
Dec-14-21 | Initiated | Goldman | Buy |
Dec-01-21 | Initiated | Seaport Research Partners | Buy |
May-19-21 | Initiated | Wells Fargo | Equal Weight |
Mar-17-21 | Downgrade | Guggenheim | Buy → Neutral |
Jan-08-21 | Upgrade | Jefferies | Hold → Buy |
Sep-17-20 | Initiated | Piper Sandler | Overweight |
Jul-01-20 | Initiated | SVB Leerink | Mkt Perform |
May-14-20 | Upgrade | Credit Suisse | Neutral → Outperform |
Sep-27-19 | Resumed | RBC Capital Mkts | Outperform |
Sep-12-19 | Initiated | Deutsche Bank | Buy |
Jun-05-19 | Upgrade | Standpoint Research | Hold → Buy |
Apr-29-19 | Downgrade | Credit Suisse | Outperform → Neutral |
Apr-18-19 | Initiated | Guggenheim | Buy |
Apr-15-19 | Downgrade | Oppenheimer | Outperform → Perform |
Apr-10-19 | Reiterated | BofA/Merrill | Buy |
Mar-13-19 | Initiated | Bernstein | Outperform |
Feb-20-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
Jan-17-19 | Initiated | UBS | Buy |
Dec-18-18 | Initiated | Barclays | Overweight |
Nov-29-18 | Resumed | Goldman | Neutral |
Nov-28-18 | Initiated | Evercore ISI | Outperform |
Oct-26-18 | Resumed | Wolfe Research | Peer Perform |
Jul-09-18 | Upgrade | Citigroup | Neutral → Buy |
Feb-27-18 | Resumed | BofA/Merrill | Buy |
Feb-13-18 | Reiterated | Citigroup | Neutral |
View All
Cvs Health Corp Stock (CVS) Latest News
Principal Financial Group Inc. Acquires 66,244 Shares of CVS Health Co. (NYSE:CVS) - MarketBeat
Jim Cramer on CVS Health Corporation (CVS): ‘CVS Is A Real Company’ - Insider Monkey
CVS Health Corp. to lay off another 164 employees connected to Aetna Hartford site - Hartford Courant
CVS Accused of Illegal Opioid Dispensing in Federal Suit - MSN
Why CVS Health (CVS) Outpaced the Stock Market Today - Yahoo Canada Finance
Varo Bank Introduces Zero Fee Cash Deposits at Participating CVS Locations - Quantisnow
Why CVS Health (CVS) Is the Best Dividend Leader to Buy According to Wall Street Analysts? - Insider Monkey
CVS class action alleges retailer allows third parties to access mobile app communications - Top Class Actions
FY2024 EPS Estimates for CVS Health Cut by Leerink Partnrs - MarketBeat
CVS Health Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Civil Lawsuit Accuses CVS Of Facilitating Unlawful Sale Of Opioid Prescriptions For Profit - RTTNews
CVS Health (NYSE:CVS) Shares Gap DownShould You Sell? - MarketBeat
Peering Into CVS Health's Recent Short Interest - Benzinga
CVS stock touches 52-week low at $43.93 amid market challenges - Investing.com Canada
Feds accuse CVS of filling ‘thousands’ of illicit opioid prescriptions - STAT
Aetna adds Spanish language capabilities for health app to better serve diverse populations - CVS Health
Aetna Adds Spanish Language Capabilities for Health App to Better Serve Diverse Populations - PR Newswire
CVS contributing to US opioid crisis, Justice Department alleges - Proactive Investors UK
DOJ files complaint against CVS for filling ’unlawful' prescriptions of opioids and seeking reimbursement for them - Fortune
Reasons to Ratain CVS Stock in Your Portfolio Now - Zacks Investment Research
CVS Health stock supported by Baird for future EPS growth once headwinds are addressed - Investing.com
PBM reform looks manageable for CVS Health, says UBS - Yahoo Finance
CVS dispensed opioid drugs unlawfully in profit push, US suit alleges - Yahoo Finance
US Justice Department sues CVS, alleging corporate practices allowed unlawful opioid prescriptions - The Boston Globe
CVS Accused of Illegal Opioid Dispensing in Whistleblower Suit - Insurance Journal
DOJ files complaint against CVS for facilitating unlawful sale of prescription opioids - NBC Philadelphia
CVS hit with civil complaint after DOJ alleges pharmacy filled unlawful prescriptions - Fox Business
CVS Fueled Opioid Epidemic In Rush For Profits, Feds Say - Law360
CVS hit with lawsuit, accused of unlawfully filling opioid prescriptions - AOL
Steps to rein in pharmacy benefit managers in US bill "manageable" for firms - Reuters
CVS Health Corp. stock outperforms competitors on strong trading day - MarketWatch
DOJ accuses CVS of violating Controlled Substances ActProvidence Business First - The Business Journals
CVS accused of illegal opioid dispensing in whistleblower suit - The Boston Globe
US healthcare spending rose 7.5% in 2023, government report says - Marketscreener.com
CVS sued by DOJ for allegedly filling 'unlawful' opioid prescriptions (CVS:NYSE) - Seeking Alpha
Justice Department files nationwide lawsuit accusing CVS of filling ‘unlawful prescriptions’ - WLNE-TV (ABC6)
DOJ sues CVS for unlawfully dispensing controlled substances - Providence Business News
US accuses CVS of filling, billing government for illegal opioid prescriptions - Reuters.com
News | BREAKING: CVS Sued by DOJ for Alleged Violations of Controlled Substances & False Claims Acts - GoLocalProv
Jim Cramer’s Bold Take: Why CVS Health (CVS) Is Struggling in Today’s Healthcare Environment - Insider Monkey
Pharmacy Benefit Managers Played Key Role in Worsening Opioid Crisis, Drug Makers Paid Staggering Rebates To Middlemen: NYT - Benzinga
What to expect from big retailers providing healthcare in 2025 - Modern Healthcare
News | CVS Took Secret Payments for “Free Flow of Opioids,” Says NY Times Investigation - GoLocalProv
CVS Health Corporation (CVS) Announces Early Results and Pricing of Cash Tender Offer - GuruFocus.com
House GOP Asks CVS How Its PBM Treats Smaller Pharmacies - Law360
Feds Intervene In $200M FCA Case Against CVS - Law360
CVS Health Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
What's Going On With CVS Health, UnitedHealth And Cigna Group Shares?CVS Health (NYSE:CVS) - Benzinga
A Closer Look at CVS Health's Options Market Dynamics - Benzinga
Trump ‘Middleman’ Remark Sinks CVS, UnitedHealth, Cigna Shares - MSN
Health Insurers Fall as Pfizer CEO Says Trump Wants PBM Reform - Yahoo Finance
Cvs Health Corp Stock (CVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):